复星医药(02196.HK):供港疫苗将直接於德国生产
复星医药(02196.HK)及BioNTech公布,其新型肺炎疫苗「复必泰」获香港特别行政区食物及卫生局认可在香港作紧急使用。未来供应香港的疫苗将直接由BioNTech在德国的工厂进行生产,用於港府新型肺炎疫苗接种计划下的供应、分发和施用等。
复星医药董事长兼首席执行官吴以芳表示,与BioNTech将密切配合港府的疫苗接种计划,以确保市民早日能接种疫苗。BioNTech首席执行官兼联合创始人Ugur Sahin表示,未来希望可尽快完成在亚洲的疫苗分配,也将继续针对潜在的病毒变异进行疫苗测试。
公布指,根据全球第三期临床试验结果显示,BioNTech的mRNA新冠疫苗已达到了所有主要疗效终点,在预防新冠病毒感染方面的有效性为95%,针对65岁以上成年人的有效性超过94%,在各个年龄、性别、种族和族群人口上呈现一致的有效性。现时,该款疫苗已获英国、美国、加拿大、欧盟等超过50个国家和地区的卫生监管部门的授权使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.